Grifols Will Divest Assets to Resolve Talecris Merger Concerns in Plasma-Derived Drugs

Grifols, S.A., a manufacturer of plasma-derived drugs, may proceed with its acquisition of Talecris Biotherapeutics Holdings Corp., a rival in the sector, provided there are significant divestitures to ameliorate projected anticompetitive effects, according to a proposed Federal Trade Commission consent order (In re Grifols, S.A.).

The FTC said the settlement aims to preserve competition and protect U.S. consumers from higher health care costs.

The proposed settlement would require Grifols to sell the Talecris fractionation facility in Melville, N.Y., and Grifols’s plasma collection centers in Mobile, Ala., and Winston-Salem, N.C., to Kedrion S.p.A.

Kedrion, a manufacturer of plasma-derived products ...